Researchers at Gene Network Sciences (GNS) are on a mission to solve the drug industry's agonizing R&D productivity problem. Their answer: predictive computer simulations designed to reduce drug discovery time by one-third and cut R&D costs in half. As they evolve, these simulations will show how human cancer and bacterial cells behave, providing insight into which protein targets or combinations thereof will yield the strongest therapeutic impact.
31 Dutch Mill Road
Ithaca, NY 14850
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.
Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.
Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.
As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.
As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.
A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.
After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.
